吉非替尼联合多西他赛治疗EGFR基因突变的非小细胞肺癌患者的效果分析

Effects of Gefitinib Combined with Docetaxel on Non-small Cell Lung Cancer Patients with EGFR Gene Mutation

目的探讨表皮生长因子受体(EGFR)基因突变的非小细胞肺癌患者应用吉非替尼联合多西他赛治疗的效果及对患者生活质量(QOL)评分的影响。方法回顾性分析我院收治的EGFR基因突变的非小细胞肺癌患者100例,将其随机分为对照组和研究组,对照组采用顺铂治疗,研究组在对照组基础上加以吉非替尼联合多西他赛治疗,对比两组患者的临床疗效、呼吸问卷评分、不良反应发生率及QOL评分。结果研究组患者的临床疗效显著优于对照组(P<0.05);治疗前两组患者的呼吸评分无显著差异(P>0.05),治疗后研究组患者呼吸评分显著低于对照组(P<0.05);治疗后研究组患者恶心呕吐、过敏、肠胃不适、中性粒细胞减少、低血糖、肝功能异常等不良反应的发生率显著低于对照组(P<0.05);治疗前两组患者QOL评分无显著差异(P>0.05),治疗后研究组患者QOL评分显著高于对照组(P<0.05)。结论采用吉非替尼联合多西他赛治疗EGFR基因突变的非小细胞肺癌,临床疗效显著,可有效减少患者不良反应发生率,改善QOL评分,提高生活质量,值得临床推广。

Objective To investigate the effects of gefitinib combined with docetaxel on non-small cell lung cancer patients with epidermal growth factor receptor(EGFR)gene mutation and its influence on quality of life(QOL)scores of patients.Methods A retrospective analysis was made on 100 non-small cell lung cancer patients with EGFR gene mutation admitted to our hospital.They were randomly divided into control group and study group.The control group was treated with cisplatin,and the study group was treated with gefitinib combined with docetaxel on the basis of treatment of control group.The clinical effect,respiratory questionnaire score,incidence of adverse reactions and QOL score of the two groups were compared.Results The clinical effect of gefitinib combined with docetaxel in patients with non-small cell lung cancer in the study group was significantly better than that in the control group(P<0.05).There was no significant difference in respiratory score between the two groups before treatment(P>0.05).But the respiratory score in the study group was significantly lower than that in the control group after treatment(P<0.05).After treatment,the incidence of nausea,vomiting,allergy,gastrointestinal discomfort,neutropenia,hypoglycemia and abnormal liver function in the study group was significantly lower than that in the control group(P<0.05).There was no significant difference in QOL scores between the two groups before treatment(P>0.05).However,after treatment,the QOL scores of patients in the study group were significantly higher than those in the control group in terms of dietary ability,mental state,sleep quality,treatment attitude,pain degree and cognitive ability(P<0.05).Conclusion Gefitinib combined with docetaxel had significant curative effect in treating non-small cell lung cancer with EGFR gene mutation.The combination treatment can effectively reduce the incidence of adverse reactions and improve the quality of life of patients.It is worthy of clinical promotion.